DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

Percutaneous Electrical Nerve Field Stimulator System for Functional Abdominal Pain Disorders (IB-Stim)

Defines medical necessity and prior authorization expectations for use of the IB-Stim percutaneous electrical nerve field stimulator in pediatric patients (ages 11-18) with Rome IV functional gastrointestinal disorders for Blue Cross Blue Shield - Rhode Island Medicare Advantage and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyPercutaneous Electrical Nerve Field Stimulator System for Functional Abdominal Pain Disorders (IB-Stim)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2025

Next Review DateJan 1, 2025

Key ActionObtain prior authorization for Medicare Advantage patients (recommended for Commercial) before IB‑Stim (CPT 0720T) when coverage criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

11-18age range specified for coverage

>=9 mominimum symptom duration required

3 classesprior medication categories

0720TCPT code

Required (MA)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for IB-Stim (PENFS)

Initial Therapy (Pediatric coverage criteria)

Covered when ALL of the following are met

Age: 11-18 years of age

applies to Medicare Advantage and Commercial Products

Diagnosis of a Rome IV defined functional gastrointestinal disorder (functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, or abdominal migraine)

Organic disease excluded: Organic GI disease must have been ruled out

Prior medication failures: Individual has tried and failed at least one medication in all three of the following categories in addition to diet modification: (1) acid suppression (H2-blockers or proton pump inhibitors); (2) neuromodulators (amitriptyline, nortriptyline, gabapentin, periactin, aprepitant); and (3) antispasmodics or motility medications (hyoscyamine, dicyclomine, erythromycin, linaclotide, prucalopride)

Symptom duration: GI symptoms have been present for at least 9 months>= 9 months

Contraindications absent: Individual does not have a history of a cardiac pacemaker, hemophilia, or psoriasis vulgaris

All uses of the percutaneous electrical nerve field stimulator system (IB‑Stim) that do not meet the specified medical criteria listed for pediatric patients are not covered for Medicare Advantage Plans and are considered not medically necessary for Commercial Products. This includes any application where one or more required elements (age, qualifying Rome IV diagnosis, exclusion of organic GI disease, prior medication trials, symptom duration, or absence of listed contraindications) are not documented.

Use of IB‑Stim is limited to patients who meet all of the following: are between 11 and 18 years of age; have a diagnosis that meets Rome IV–defined functional gastrointestinal disorder (including functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, or abdominal migraine); have had organic GI disease ruled out; have GI symptoms present for at least 9 months; have tried and failed at least one medication in each of the three specified categories (acid suppression with H2‑blockers or PPIs; neuromodulators such as amitriptyline, nortriptyline, gabapentin, periactin, or aprepitant; and antispasmodics or motility medications such as hyoscyamine, dicyclomine, erythromycin, linaclotide, or prucalopride) in addition to diet modification; and do not have a history of a cardiac pacemaker, hemophilia, or psoriasis vulgaris.

Coding

Covered CPT CodesCPTCovered

0720T

Percutaneous electrical nerve field stimulation, cranial nerves, without implantation

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage plans and recommended for Commercial products. Submit prior authorization requests per payer instructions before initiating therapy.

Prior authorization required for Medicare Advantage
Prior authorization recommended for Commercial Products

Documentation Required

Verify Member Benefits and Eligibility

Before providing services, verify member benefits and eligibility. Coverage and benefit determinations are subject to the member's subscriber agreement, member certificate, or employer agreement. Contact the provider call center for member-specific benefit information. Do not charge members for services determined to be not medically necessary or non-covered benefits unless the member has been informed and has agreed in writing to accept financial responsibility.

Verify benefits/eligibility per subscriber agreement or employer agreement

Background

Abdominal pain–related functional gastrointestinal disorders in pediatric patients are conditions characterized by persistent GI symptoms without an identified organic cause (examples include irritable bowel syndrome, functional dyspepsia, functional abdominal pain, and abdominal migraine). The IB‑Stim device is intended as a neuromodulatory therapy for adolescents meeting Rome IV criteria; treatment is considered only after organic causes are excluded and after required trials of dietary modification and medications have failed.

Definitions

IB-Stim / PENFS — device definition and FDA clearance details

Device nameIB-Stim (PENFS)

Device typePercutaneous electrical nerve field stimulator (auricular)

FDA statusFDA-cleared auricular device (Neuro-Stim/IB-Stim, Innovative Health Solutions)

MechanismUses alternating frequencies to stimulate branches of cranial nerves V, VII, IX, and X in the external ear to modulate central pathways

Typical treatment regimen5-day (120 hour) application worn for 3 consecutive weeks

Rome IV functional GI disorder — definition and included diagnoses

Definition (Rome IV)

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyPercutaneous Electrical Nerve Field Stimulator System for Functional Abdominal Pain Disorders (IB-Stim)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2025

Next Review DateJan 1, 2025

Key ActionObtain prior authorization for Medicare Advantage patients (recommended for Commercial) before IB‑Stim (CPT 0720T) when coverage criteria are met.

SourceLink

On This Page

Contact provider call center for member-specific benefits

Obtain written member agreement before billing for non-covered services

Step Therapy

Medication Trial Requirement

For coverage consideration, the individual must have tried and failed at least one medication in each of the following three categories in addition to diet modification: acid suppression (H2-blockers or proton pump inhibitors), neuromodulators (e.g., amitriptyline, nortriptyline, gabapentin, periactin, aprepitant), and antispasmodics or motility agents (e.g., hyoscyamine, dicyclomine, erythromycin, linaclotide, prucalopride). Document prior trials and failures in the medical record and include supporting documentation with any prior authorization request.

Document trial and failure of at least one agent from each category: acid suppression; neuromodulators; antispasmodics/motility agents
Include documentation of dietary modification attempts
Attach medication trial documentation to prior authorization when applicable

Denial Risk

Coverage Denial for Criteria Non‑Compliance

Services that do not meet the policy criteria are not covered for Medicare Advantage plans and are not medically necessary for Commercial products.

Noncoverage applies when the policy criteria (including medication trials and benefit eligibility) are not met

Group of functional gastrointestinal disorders with symptoms not attributable to other conditions; includes disorders driven by abdominal pain

Included diagnosesFunctional abdominal pain; Functional abdominal pain syndrome; Irritable bowel syndrome (IBS); Functional dyspepsia; Abdominal migraine

Clinical noteThese disorders are associated with higher disability and reduced quality of life in children

Requirement for device coverageDiagnosis must meet Rome IV definition (one of the listed disorders) and organic GI disease must be ruled out